Elderly patients with severe cardiopulmonary and other system dysfunctions are unable to tolerate pulmonary lobectomy. This study aimed to evaluate the risk and efficacy of wedge resection under video-assisted thoracoscopic surgery (VATS) on elderly high-risk patients with stage I peripheral non-small-cell lung cancer (PNSCLC).
Methods:
Elderly patients (=70 years) with suspected PNSCLC were divided into high-risk group and conventional risk group.
The high-risk patients confirmed in stage I by the examination of positron emission tomography computed tomography (PET-CT) and the postoperative patients in stage I PNSCLC with negative incisal margin were treated with VATS wedge resection. The conventional risk patients were treated with VATS radical resection and systematic lymphadenectomy.
The clinical and pathological data were recorded. The total survival, tumor-free survival, recurrence time and style of patients were followed up.
Results:
The operative time and blood loss of the VATS wedge resection group (69.4 +/- 15.5 min, 52.1 +/- 11.2 ml) were significantly less than those of the VATS radical resection group (128 +/- 35.5 min, 217.9 +/- 87.1 ml).
Neither groups had postoperative death. The overall and tumor-free survival rate of the VATS wedge resection group within three years were 66.7% and 60.0%, and those of the VATS radical resection group were 93.8% and 94.1%, without significant difference (P 0.05).
The recurrence rates of the VATS wedge resection group and VATS radical resection group were 14.3% and 3.0%, without significant difference (P 0.05).
Conclusion:
It is safe, minimally invasive and meaningful to perform VATS wedge resection on the elderly high-risk patients with stage I PNSCLC.
Author: Ling LinDingzhong HuChenxi ZhongHeng Zhao
Credits/Source: Journal of Cardiothoracic Surgery 2013, 8:231
Published on: 2013-12-21
Tweet
News Provider: EUPB – European Press Bureau
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.